Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K DATED AUGUST 23, 2011 - UROLOGIX INC | urologix113944_8k.htm |
| EX-99.1 - PRESS RELEASE DATED AUGUST 23, 2011 - UROLOGIX INC | urologix113944_ex99-1.htm |
Exhibit 99.2
Certain Remarks of Brian J. Smrdel
Urologix, Inc. Teleconference
August 23, 2011
| • | On a trailing 12-month sales basis, our days sales outstanding at the end of the fourth quarter [of fiscal year 2011] was 38 days, similar to the end of the third quarter of fiscal 2011 but up from 34 days at June 30, 2010. | |
| • | The decrease in operating expense [in the fourth quarter of fiscal year 2011] when compared to the third quarter is a result of a $75,000 decrease in sales and marketing expense, partially offset by a $30,000 increase in research and development expense as the Company continued its investment in product and clinical research efforts. |